1. Event-Free Survival after 68Ga-PSMA-11 PET/CT in recurrent Hormone-Sensitive Prostate Cancer (HSPC) patients eligible for Salvage Therapy
- Author
-
Valeria Chiofalo, Roberto Passera, Serena Grimaldi, Désirée Deandreis, Guido Rovera, Paolo Gontero, Umberto Ricardi, Francesco Ceci, Giuseppe Carlo Iorio, Sara Dall’Armellina, Marilena Bellò, Marco Oderda, Virginia Liberini, and Alessia Guarneri
- Subjects
Oncology ,medicine.medical_specialty ,PET-CT ,Prostate cancer ,PSMA PET ,business.industry ,Urology ,Event-free survival ,Event free survival ,Salvage therapy ,General Medicine ,Prostate cancer survival ,Hormone-sensitive prostate cancer ,urologic and male genital diseases ,68Ga-PSMA-11 ,Hormone sensitive prostate cancer ,Internal medicine ,Medicine ,Radiology, Nuclear Medicine and imaging ,business - Abstract
Background/aim Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who performed PSMA-PET are needed. The aim of this study was to evaluate the incidence of clinically relevant events during follow-up in patients who performed PSMA-PET for BCR after radical treatment. Materials and methods This analysis included consecutive, hormone-sensitive, hormone-free, recurrent PCa patients (HSPC) enrolled through a prospective study. All patients were eligible for salvage therapy, having at least 24 months of follow-up after PSMA-PET. The primary endpoint was the Event-Free Survival (EFS), defined as the time between the PSMA-PET and the date of event/last follow-up. The Kaplan–Meier method was used to estimate the EFS curves. EFS was also investigated by Cox proportional hazards regression. Events were defined as death, radiological progression, or PSA recurrence after therapy. Results One-hundred and seventy-six (n = 176) patients were analyzed (median PSA 0.62 [IQR: 0.43–1.00] ng/mL; median follow-up of 35.4 [IQR: 26.5–40.3] months). The EFS was 78.8% at 1 year, 65.2% (2 years), and 52.2% (3 years). Patients experiencing events during study follow-up had a significantly higher median PSA (0.81 [IQR: 0.53–1.28] vs 0.51 [IQR: 0.36–0.80] ng/mL) and a lower PSA doubling time (PSAdt) (5.4 [IQR: 3.7–11.6] vs 12.7 [IQR: 6.6–24.3] months) (p 0.5 ng/mL, PSAdt ≤ 6 months, and a positive PSMA-PET result were associated with a higher event rate (p 0.5 ng/mL and PSAdt ≤ 6 months were statistically significant event-predictors in multivariate model (p Conclusion Low PSA and long PSAdt were significant predictors of longer EFS. A lower incidence of events was observed in patients having negative PSMA-PET, since longer EFS was significantly more probable in case of a negative scan.
- Published
- 2021
- Full Text
- View/download PDF